These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 30718507)

  • 1. Generation and characterization of novel anti-DR4 and anti-DR5 antibodies developed by genetic immunization.
    Dubuisson A; Favreau C; Fourmaux E; Lareure S; Rodrigues-Saraiva R; Pellat-Deceunynck C; El Alaoui S; Micheau O
    Cell Death Dis; 2019 Feb; 10(2):101. PubMed ID: 30718507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual Agonist Surrobody Simultaneously Activates Death Receptors DR4 and DR5 to Induce Cancer Cell Death.
    Milutinovic S; Kashyap AK; Yanagi T; Wimer C; Zhou S; O'Neil R; Kurtzman AL; Faynboym A; Xu L; Hannum CH; Diaz PW; Matsuzawa S; Horowitz M; Horowitz L; Bhatt RR; Reed JC
    Mol Cancer Ther; 2016 Jan; 15(1):114-24. PubMed ID: 26516157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predominant antitumor effects by fully human anti-TRAIL-receptor 2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo.
    Nagane M; Shimizu S; Mori E; Kataoka S; Shiokawa Y
    Neuro Oncol; 2010 Jul; 12(7):687-700. PubMed ID: 20511188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis of LaDR5, a novel agonistic anti-death receptor 5 (DR5) monoclonal antibody, to inhibit DR5/TRAIL complex formation.
    Qiao C; Hu M; Guo L; Lv M; Lin Z; Geng J; Lang X; Li X; Li Y; Ma Y; Feng J; Shen B
    BMC Immunol; 2012 Jul; 13():40. PubMed ID: 22788777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparation and characterization of a set of monoclonal antibodies to TRAIL and TRAIL receptors DR4, DR5, DcR1, and DcR2.
    Liu XS; Zhu Y; Han WN; Li YN; Chen LH; Jia W; Song CJ; Liu F; Yang K; Li Q; Jin BQ
    Hybrid Hybridomics; 2003 Apr; 22(2):121-5. PubMed ID: 12831538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of TRAIL resistance in colon carcinoma cells: different contributions of DR4 and DR5.
    van Geelen CM; Pennarun B; Le PT; de Vries EG; de Jong S
    BMC Cancer; 2011 Jan; 11():39. PubMed ID: 21272366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel anti-DR5 antibody-drug conjugate possesses a high-potential therapeutic efficacy for leukemia and solid tumors.
    Zhang S; Zheng C; Zhu W; Xiong P; Zhou D; Huang C; Zheng D
    Theranostics; 2019; 9(18):5412-5423. PubMed ID: 31410224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5.
    Lemke J; Noack A; Adam D; Tchikov V; Bertsch U; Röder C; Schütze S; Wajant H; Kalthoff H; Trauzold A
    J Mol Med (Berl); 2010 Jul; 88(7):729-40. PubMed ID: 20354842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction.
    Zhou L; Wang W; Dicker DT; Humphreys RC; El-Deiry WS
    Cancer Biol Ther; 2011 Aug; 12(4):335-48. PubMed ID: 21785270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of a novel anti-DR5 monoclonal antibody WD1 with the potential to induce tumor cell apoptosis.
    Wang J; Lin Z; Qiao CX; Lv M; Yu M; Xiao H; Wang Q; Wang L; Feng J; Shen B; Ma Y; Li Y
    Cell Mol Immunol; 2008 Feb; 5(1):55-60. PubMed ID: 18318995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down-regulation of Cbl-b by bufalin results in up-regulation of DR4/DR5 and sensitization of TRAIL-induced apoptosis in breast cancer cells.
    Yan S; Qu X; Xu C; Zhu Z; Zhang L; Xu L; Song N; Teng Y; Liu Y
    J Cancer Res Clin Oncol; 2012 Aug; 138(8):1279-89. PubMed ID: 22447040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel agonistic antibody to human death receptor 4 induces apoptotic cell death in various tumor cells without cytotoxicity in hepatocytes.
    Sung ES; Park KJ; Lee SH; Jang YS; Park SK; Park YH; Kwag WJ; Kwon MH; Kim YS
    Mol Cancer Ther; 2009 Aug; 8(8):2276-85. PubMed ID: 19638452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5.
    Adams C; Totpal K; Lawrence D; Marsters S; Pitti R; Yee S; Ross S; Deforge L; Koeppen H; Sagolla M; Compaan D; Lowman H; Hymowitz S; Ashkenazi A
    Cell Death Differ; 2008 Apr; 15(4):751-61. PubMed ID: 18219321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic ligands of death receptor 5 display a cell-selective agonistic effect at different oligomerization levels.
    Beyrath J; Chekkat N; Smulski CR; Lombardo CM; Lechner MC; Seguin C; Decossas M; Spanedda MV; Frisch B; Guichard G; Fournel S
    Oncotarget; 2016 Oct; 7(40):64942-64956. PubMed ID: 27409341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD11c+ dendritic cells and B cells contribute to the tumoricidal activity of anti-DR5 antibody therapy in established tumors.
    Haynes NM; Hawkins ED; Li M; McLaughlin NM; Hämmerling GJ; Schwendener R; Winoto A; Wensky A; Yagita H; Takeda K; Kershaw MH; Darcy PK; Smyth MJ
    J Immunol; 2010 Jul; 185(1):532-41. PubMed ID: 20505139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TRAIL-R2 (DR5) mediates apoptosis of synovial fibroblasts in rheumatoid arthritis.
    Ichikawa K; Liu W; Fleck M; Zhang H; Zhao L; Ohtsuka T; Wang Z; Liu D; Mountz JD; Ohtsuki M; Koopman WJ; Kimberly R; Zhou T
    J Immunol; 2003 Jul; 171(2):1061-9. PubMed ID: 12847280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TRAIL induces apoptosis in oral squamous carcinoma cells--a crosstalk with oncogenic Ras regulated cell surface expression of death receptor 5.
    Chen JJ; Mikelis CM; Zhang Y; Gutkind JS; Zhang B
    Oncotarget; 2013 Feb; 4(2):206-17. PubMed ID: 23470485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pro-survival effects by NF-κB, Akt and ERK(1/2) and anti-apoptosis actions by Six1 disrupt apoptotic functions of TRAIL-Dr4/5 pathway in ovarian cancer.
    Yang J; Li G; Zhang K
    Biomed Pharmacother; 2016 Dec; 84():1078-1087. PubMed ID: 27780136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and characterization of a novel agonistic anti-DR4 human monoclonal antibody.
    Feng Y; Xiao X; Zhu Z; Dimitrov DS
    MAbs; 2010; 2(5):565-70. PubMed ID: 20581445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. APG350 induces superior clustering of TRAIL receptors and shows therapeutic antitumor efficacy independent of cross-linking via Fcγ receptors.
    Gieffers C; Kluge M; Merz C; Sykora J; Thiemann M; Schaal R; Fischer C; Branschädel M; Abhari BA; Hohenberger P; Fulda S; Fricke H; Hill O
    Mol Cancer Ther; 2013 Dec; 12(12):2735-47. PubMed ID: 24101228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.